2025 Full Year Results and Business Updates

Summary by AI BETAClose X

HUTCHMED (China) Limited reported a net income of $456.9 million for the year ended December 31, 2025, a significant increase from $37.7 million in the prior year, largely driven by a $415.8 million divestment gain and profitable core operations. The company's cash balance stood at $1.4 billion at year-end. Key product FRUZAQLA® (fruquintinib ex-China) saw in-market sales rise 26% to $366.2 million, while ELUNATE® (fruquintinib in China) generated $100.1 million in sales. HUTCHMED also advanced its Antibody-Targeted Therapy Conjugate (ATTC) platform, initiating its first clinical trial for HMPL-A251 and planning further ATTC candidate trials and potential partnerships in 2026. The company provided 2026 guidance for Oncology/Immunology consolidated revenue between $330 million and $450 million.

Disclaimer*

UK 100

Latest directors dealings